Calidi Biotherapeutics, a biotechnology company specializing in innovative cancer immunotherapy, will host a critical investor webinar on April 24, 2025, to spotlight its emerging cancer treatment platforms. Led by newly appointed Chief Medical Officer Dr. Guy Travis Clifton, the event will provide comprehensive insights into the company's cutting-edge stem cell-based delivery technologies targeting multiple oncological indications.
The webinar will feature detailed presentations on three key therapeutic candidates: CLD-201, CLD-400, and CLD-101. CLD-201, which has already received FDA clearance, is specifically designed to advance trials for solid tumor treatments. CLD-400 will focus on metastatic and lung cancer interventions, while CLD-101 targets high-grade gliomas, representing a comprehensive approach to addressing various complex cancer types.
Calidi's proprietary technology represents a significant advancement in cancer immunotherapy by utilizing allogeneic stem cells capable of delivering oncolytic viruses. This innovative approach aims to enhance treatment efficacy while potentially improving patient safety. The company's platform uniquely combines stem cell delivery mechanisms with viral payloads, creating a dual strategy that could potentially treat or even prevent metastatic disease.
The scientific community has long sought more targeted and effective cancer treatments that minimize collateral damage to healthy tissues. Calidi's approach potentially addresses this challenge by using stem cells as protective carriers for oncolytic viruses, which can selectively target and destroy cancer cells. This method could represent a paradigm shift in how aggressive cancers are approached, offering hope for patients with difficult-to-treat malignancies.
During the webinar, investors and researchers will have an opportunity to gain deeper understanding of the company's technological platforms through a live Q&A session following the presentation. The event underscores Calidi Biotherapeutics' commitment to advancing cancer treatment through innovative, targeted therapeutic approaches.
